A negative sentinel lymph node (SLN) biopsy spares many breast cancer patients the complications associated with lymph node irradiation or additional surgery. However, patients at high risk for nodal involvement based on clinical characteristics may remain at unacceptably high risk of axillary disease even after a negative SLN biopsy result. A Bayesian nomogram was designed to combine the probability of axillary disease prior to nodal biopsy with customized test characteristics for an SLN biopsy and provides the probability of axillary disease despite a negative SLN biopsy. Users may individualize the sensitivity of an SLN biopsy based on factors known to modify the sensitivity of the procedure. This tool may be useful in identifying patients who should have expanded upfront exploration of the axilla or comprehensive axillary irradiation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262582 | PMC |
http://dx.doi.org/10.4061/2011/973245 | DOI Listing |
Int J Mol Sci
January 2025
Department of Oncology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Sentinel lymph node (SLN) detection has been widely investigated in recent years as a part of the surgical staging of women with endometrial cancer (EC), gradually overtaking lymphadenectomy (LND) in this respect. In this study, thirty EC patients, assumed as stage I, were investigated using superparamagnetic iron oxide (SPIO) as a tracer for SLN detection followed by LND. The endpoints of this research were the proportion of successful SLN detection, the average number of SLNs per patient, the percentage of bilaterally detected SLNs, and the proportion of metastatic SLNs.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Laboratory of Cancer Genetics, Department of Pathology, Polish Mother's Memorial Hospital Research Institute, Rzgowska 281/289, 93-338 Lodz, Poland.
Breast cancer is one of the most common cancers diagnosed in both countries with high and low levels of socio-academic development. Routine, regular screening tests being introduced in an increasing number of countries make it possible to detect breast cancer at an early stage of development, as a result of which the trend in the incidence of metastatic breast cancer has been decreasing in recent years. The latest guidelines for the treatment of this tumor do not recommend axillary dissection, which limits the need for rapid assessment of the nodes during surgery.
View Article and Find Full Text PDFCir Esp (Engl Ed)
January 2025
Consorcio Sanitario del Maresme, Hospital de Mataró, Mataró, Spain.
Introduction: Sentinel lymph node (SLN) detection is the technique of choice for staging early-stage breast cancer (BC). The preferred technique for SLN detection is labeling with the radioisotope Technetium-99 (Tc-99). Other methods have been evaluated, including methylene blue, magnetic tracers, iodine seeds, or fluorescent substances.
View Article and Find Full Text PDFJ Am Coll Surg
January 2025
The Hiram C. Polk Jr., MD Department of Surgery, University of Louisville, Louisville, KY.
Background: The definition of T1b cutaneous melanoma was changed in the 8th edition of the AJCC staging system based on survival differences but not risk of sentinel lymph node (SLN) metastases. We sought to evaluate changes in SLN biopsy (SLNB) use and rates of positive SLNB in response to updated staging criteria, and to evaluate the incidence of high-risk features in T1a melanoma in whom SLNB is now recommended.
Study Design: The 2021 National Cancer Database Melanoma PUF was used to obtain SLNB utilization and positivity rates in T1 (thin) melanoma (thickness ≤1.
ACS Appl Mater Interfaces
January 2025
Sixth People's Hospital, School of Medicine & School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, P. R. China.
The use of dual-tracer contrast agents in clinical applications, such as sentinel lymph node (SLN) identification, offers significant advantages including enhanced accuracy, sensitivity, as well as comprehensive and multimodal visualization. In the current clinical practice, SLNs are typically marked prior to surgical resection by multiple and sequential injections of two tracers, the radioactive tracer and methylene blue (MB) dye. This imposes physical and psychological burden on patients and medical staff.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!